AR053633A1 - Metodos para purificar proteinas que contienen una region fc - Google Patents

Metodos para purificar proteinas que contienen una region fc

Info

Publication number
AR053633A1
AR053633A1 ARP060102573A ARP060102573A AR053633A1 AR 053633 A1 AR053633 A1 AR 053633A1 AR P060102573 A ARP060102573 A AR P060102573A AR P060102573 A ARP060102573 A AR P060102573A AR 053633 A1 AR053633 A1 AR 053633A1
Authority
AR
Argentina
Prior art keywords
methods
region
polypeptides
proteins containing
purification
Prior art date
Application number
ARP060102573A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053633A1 publication Critical patent/AR053633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP060102573A 2005-06-17 2006-06-16 Metodos para purificar proteinas que contienen una region fc AR053633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69182105P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
AR053633A1 true AR053633A1 (es) 2007-05-09

Family

ID=37433887

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060102573A AR053633A1 (es) 2005-06-17 2006-06-16 Metodos para purificar proteinas que contienen una region fc
ARP060102572A AR053632A1 (es) 2005-06-17 2006-06-16 Metoddos para purificar anticuerpos anti a beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060102572A AR053632A1 (es) 2005-06-17 2006-06-16 Metoddos para purificar anticuerpos anti a beta

Country Status (25)

Country Link
US (3) US7825223B2 (enExample)
EP (3) EP2388274A1 (enExample)
JP (2) JP5270337B2 (enExample)
KR (2) KR101307614B1 (enExample)
CN (3) CN101213211A (enExample)
AR (2) AR053633A1 (enExample)
AU (2) AU2006259298B2 (enExample)
BR (2) BRPI0611600B8 (enExample)
CA (2) CA2611816C (enExample)
CR (2) CR9576A (enExample)
EA (2) EA201100177A1 (enExample)
EC (1) ECSP088086A (enExample)
ES (2) ES2402650T3 (enExample)
IL (2) IL187642A (enExample)
MA (1) MA29609B1 (enExample)
MX (2) MX2007015051A (enExample)
MY (1) MY144484A (enExample)
NI (1) NI200700329A (enExample)
NO (2) NO20076056L (enExample)
NZ (1) NZ565044A (enExample)
RU (1) RU2415865C2 (enExample)
SG (1) SG162806A1 (enExample)
TW (2) TWI372763B (enExample)
WO (2) WO2006138737A2 (enExample)
ZA (2) ZA200710330B (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
SG156672A1 (en) * 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101213211A (zh) 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
KR101591223B1 (ko) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
SG173385A1 (en) * 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
ZA200900836B (en) * 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
LT2061803T (lt) * 2006-08-28 2019-11-25 Ares Trading Sa Fc turinčių baltymų gryninimo būdas
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US20090155249A1 (en) * 2007-06-12 2009-06-18 Ac Immune S.A. Humanized antibody igg1
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
NZ585110A (en) * 2007-10-05 2012-09-28 Genentech Inc Method and compositions for diagnosis and treatment of amyloidosis
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
EP2650308A3 (en) * 2007-10-05 2014-11-12 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
RU2498991C2 (ru) * 2007-10-30 2013-11-20 Дженентек, Инк. Очистка антител с помощью катионообменной хроматографии
WO2009064424A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Tunable affinity ligands for the separation and detection of target substances
KR101247374B1 (ko) * 2008-06-26 2013-03-26 한국생명공학연구원 면역글로불린 Ｇ의 Ｆｃ 부위에 선택적으로 결합하는 신규펩타이드 및 그의 제조방법
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
MX2011004199A (es) * 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
TWI610936B (zh) * 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
CN118324847A (zh) 2008-10-29 2024-07-12 阿布林克斯公司 单域抗原结合性分子的纯化方法
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR20110086184A (ko) 2008-12-22 2011-07-27 에프. 호프만-라 로슈 아게 면역글로불린 정제
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
EP2982690B1 (en) 2009-04-30 2021-01-27 Ablynx N.V. Method for the production of domain antibodies
CN102686738A (zh) 2009-09-01 2012-09-19 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
EP2918574A1 (en) * 2009-12-31 2015-09-16 Groupe Novasep SAS Purification of succinic acid from the fermentation broth containing ammonium succinate
EP2542567B1 (de) * 2010-03-05 2020-02-12 Boehringer Ingelheim International Gmbh Selektive anreicherung von antikörpern
WO2011110598A1 (en) * 2010-03-10 2011-09-15 F. Hoffmann-La Roche Ag Method for purifying immunoglobulin solutions
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012099576A1 (en) * 2011-01-18 2012-07-26 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
KR102058254B1 (ko) 2011-03-29 2019-12-20 글락소스미스클라인 엘엘씨 단백질 정제용 완충제 시스템
SG10201604554WA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
WO2013013193A1 (en) * 2011-07-20 2013-01-24 Zepteon, Incorporated Polypeptide separation methods
US9994610B2 (en) * 2011-10-19 2018-06-12 Roche Glycart Ag Separation method for fucosylated antibodies
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
NZ718144A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
AR100716A1 (es) * 2014-06-02 2016-10-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies Producción de fragmentos fc
JP6451118B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体の分離方法
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105175548B (zh) * 2015-08-13 2019-02-05 齐鲁制药有限公司 重组人血管内皮生长因子受体-抗体融合蛋白的纯化方法
KR102691585B1 (ko) 2015-08-21 2024-08-05 에프. 호프만-라 로슈 아게 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
SI3337817T1 (sl) * 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
EP3344643B1 (en) * 2015-09-04 2025-07-02 Qiagen Sciences LLC Methods for co-isolation of nucleic acids and proteins
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
HUE067896T2 (hu) 2016-04-27 2024-11-28 Abbvie Mfg Management Unlimited Company Olyan betegségek kezelési módszerei az anti-IL-13 antitestek alkalmazásával, amelyekben az IL-13 aktivitás káros
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
WO2018018011A2 (en) * 2016-07-22 2018-01-25 Amgen Inc. Methods of purifying fc-containing proteins
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
JP2018167260A (ja) * 2017-03-29 2018-11-01 三菱ケミカル株式会社 イオン交換体の保存方法、生理活性物質の精製装置及び生理活性物質の精製方法
ES2887046T3 (es) * 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
JP7496316B2 (ja) 2018-04-24 2024-06-06 キアゲン サイエンシーズ， エルエルシー 複雑な試料からの核酸の単離および阻害物質の除去
US20220314142A1 (en) * 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CN112409477B (zh) * 2019-08-21 2022-11-08 广东菲鹏生物有限公司 IgM纯化方法
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
EP4142792A4 (en) * 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
CN113968909A (zh) * 2020-07-22 2022-01-25 信达生物制药(苏州)有限公司 一种双特异性抗体的纯化方法
UY39337A (es) 2020-07-23 2022-02-25 Othair Prothena Ltd Anticuerpos anti-abeta
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) * 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5112952A (en) * 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
SI0950067T1 (sl) * 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
WO1998047343A2 (en) * 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1385545B1 (en) 2001-04-30 2009-01-07 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
ATE409047T1 (de) * 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
WO2003015691A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
EP2048154B2 (en) 2002-02-05 2015-06-03 Genentech, Inc. Protein purification
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006516639A (ja) 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US20040229330A1 (en) * 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
EP1601697B1 (en) 2003-02-28 2007-05-30 Lonza Biologics plc Antibody purification by Protein A and ion exchange chromatography
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
DK2336172T3 (en) 2003-10-27 2015-01-26 Wyeth Llc The removal of aggregates of high molecular weight by hydroxylapatite chromatography
PL1701968T3 (pl) * 2003-12-17 2015-11-30 Wyeth Llc Koniugaty nośników z peptydami immunogennymi i sposoby ich wytwarzania
EP2479184A3 (en) * 2003-12-17 2013-09-04 Janssen Alzheimer Immunotherapy Beta immunogenic peptide carrier conjugates and methods of producing the same
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1767217A1 (en) 2004-07-14 2007-03-28 Astellas Pharma Inc. Agent for promoting the recovery from dysfunction after the onset of central neurological disease
EP1797182A2 (en) 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
CN101213211A (zh) 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー 脳アミロイド血管症の予防および治療
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
MA29609B1 (fr) 2008-07-01
TWI372763B (en) 2012-09-21
US7820799B2 (en) 2010-10-26
EP1896504B1 (en) 2012-11-21
CA2611815A1 (en) 2006-12-28
CN104926938A (zh) 2015-09-23
CA2611816C (en) 2014-05-27
WO2006138553A3 (en) 2007-02-22
ES2402650T3 (es) 2013-05-07
CR9576A (es) 2008-03-06
MY144484A (en) 2011-09-30
RU2415865C2 (ru) 2011-04-10
MX2007015952A (es) 2008-03-07
CN104926938B (zh) 2019-06-04
MX2007015051A (es) 2008-01-18
EA200800083A1 (ru) 2008-06-30
TW200840821A (en) 2008-10-16
SG162806A1 (en) 2010-07-29
BRPI0611600B8 (pt) 2021-05-25
BRPI0611600B1 (pt) 2021-04-13
KR101247836B1 (ko) 2013-03-28
CR9582A (es) 2008-05-05
AU2006261185B2 (en) 2012-02-16
JP2008543881A (ja) 2008-12-04
KR101307614B1 (ko) 2013-09-13
KR20080059371A (ko) 2008-06-27
NI200700329A (es) 2015-04-21
AU2006261185A1 (en) 2006-12-28
ECSP088086A (es) 2008-02-20
JP5150488B2 (ja) 2013-02-20
WO2006138737A3 (en) 2007-03-22
CN101365722A (zh) 2009-02-11
NO20076082L (no) 2007-12-27
US20070072307A1 (en) 2007-03-29
KR20080023315A (ko) 2008-03-13
NO20076056L (no) 2008-01-11
EA201100177A1 (ru) 2011-06-30
IL187642A (en) 2014-08-31
IL187683A (en) 2015-02-26
AU2006259298A1 (en) 2006-12-28
EA015148B1 (ru) 2011-06-30
AR053632A1 (es) 2007-05-09
ZA200710330B (en) 2009-12-30
RU2007143162A (ru) 2009-08-10
US20070082367A1 (en) 2007-04-12
ZA200710331B (en) 2009-04-29
JP2008543868A (ja) 2008-12-04
BRPI0611599A2 (pt) 2011-02-22
IL187642A0 (en) 2008-03-20
AU2006259298B2 (en) 2012-06-14
EP2388274A1 (en) 2011-11-23
US20110160437A1 (en) 2011-06-30
WO2006138737A8 (en) 2007-12-13
ES2405079T3 (es) 2013-05-30
US8440799B2 (en) 2013-05-14
US7825223B2 (en) 2010-11-02
WO2006138553A2 (en) 2006-12-28
EP1896504A2 (en) 2008-03-12
EP1896506B1 (en) 2013-01-02
NZ565044A (en) 2010-05-28
TW200740839A (en) 2007-11-01
IL187683A0 (en) 2008-08-07
WO2006138737A2 (en) 2006-12-28
HK1117174A1 (en) 2009-01-09
JP5270337B2 (ja) 2013-08-21
CA2611816A1 (en) 2006-12-28
CN101213211A (zh) 2008-07-02
BRPI0611600A2 (pt) 2011-03-15
EP1896506A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
AR053633A1 (es) Metodos para purificar proteinas que contienen una region fc
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
BR112012024550A2 (pt) processo para purificação de proteínas dependentes de vitamina k tal como o fator de coagulação ix
BR112013030628A2 (pt) "métodos para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade (ca), e de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando a coluna de proteína a".
EA200970230A1 (ru) СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
PE20091434A1 (es) Purificacion de anticuerpos por cromatografia de intercambio cationico
TR201906652T4 (tr) Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
BR112014015101A2 (pt) cromatografia de membrana de troca iônica
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
MX2013015323A (es) Polipeptidos de fusion de serpina y metodos de uso de los mismos.
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
MX395730B (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
RU2019109975A (ru) Способы очистки антител
DK2264069T3 (da) Rensning af fibrinogen
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
BR112012015169A2 (pt) "preparação de fluxo com viscosidade dinâmica aumentada contendo k2alf5 desidratado, método para a produção do mesmo e método para o uso do mesmo."
MX2024010249A (es) Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a.
BR112015029300A2 (pt) Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit
RU2018138445A (ru) Способ очистки белка
EA201391605A1 (ru) Способы очистки вирусов с использованием гельпроникающей хроматографии
AR076948A1 (es) Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos
DE60143074D1 (de) Immunmodulation mit rezeptorinduziertem tod durch apoptosis
TH85813A (th) วิธีการในการทำให้เอฟซี รีเจียน (Fc Region) บริสุทธิ์ซึ่งประกอบด้วยโปรตีน
JP5089924B2 (ja) ＩｇＭ型抗体の精製方法、ＩｇＭ型抗体認識抗原の吸着材

Legal Events

Date Code Title Description
FB Suspension of granting procedure